Beyond the biopsy: the new era of non-invasive staging and biomarkers in colorectal cancer

Abstract

Colorectal cancer (CRC) management is increasingly challenged by shifting demographics, notably the rise in aggressive early-onset CRC, and the limitations of conventional anatomical staging. This comprehensive review explores the paradigm shift toward noninvasive and minimally invasive pre-operative biomarkers for CRC diagnosis, staging, and prognostic stratification. While traditional colonoscopy and radiological imaging often fail to capture intratumoral heterogeneity and micrometastatic dissemination, emerging biomarker modalities offer real-time, high-fidelity tumor phenotyping. Advanced fecal tests and microbiome profiling, highlighting enriched taxa like Fusobacterium nucleatum , provide crucial insights into the tumor microenvironment, disease progression, and localized immune evasion. Concurrently, accessible systemic immune-inflammatory scores, such as the pan-immune-inflammation value (PIV), systemic immune-inflammation index (SII), and the cancer-specific Glasgow prognostic score (C-GPS), demonstrate robust capabilities in predicting overall survival, disease recurrence, and pathological complete response. The clinical maturation of circulating tumor DNA (ctDNA) represents a cornerstone of this evolution, offering unparalleled sensitivity for detecting molecular residual disease (MRD) post-surgery and dynamically guiding adjuvant chemotherapy de-escalation or escalation protocols. Ultimately, the future of CRC precision oncology relies on multimodal convergence, synergistically integrating liquid biopsies, radiomics, and clinical scores into unified predictive models or “Digital Twins”. Emphasizing the need for multi-center standardization and prospective validation, this integrated noninvasive biomarker landscape promises to overcome current diagnostic blind spots, optimize therapeutic interventions, and fundamentally individualize patient care.